What "drug test" actually means

Most workplace drug testing is one of two formats. A 5-panel test screens for amphetamines, cocaine metabolites, marijuana (THC-COOH), opiates (morphine, codeine), and PCP. A 10-panel test adds benzodiazepines, barbiturates, methadone, methaqualone, and propoxyphene. Both are immunoassay-based: they use antibodies that bind specific compounds or their metabolites and produce a measurable signal when those substances are present above a defined threshold.

Mitragynine and 7-hydroxymitragynine — kratom's two main alkaloids — are not in any of those antibody libraries. There is no panel of the standard 5/10-panel test that will return positive for kratom use, no matter how recent or how heavy the use was.

Specialty kratom panels — what they are and who uses them

Specialty kratom panels exist, and they work. Major reference laboratories including LabCorp and Quest Diagnostics offer extended urine-drug-screen panels that explicitly include mitragynine and 7-OH detection using LC-MS/MS — liquid chromatography tandem mass spectrometry. These are highly accurate and can identify mitragynine in urine at very low concentrations.

However, they have to be ordered specifically. They are not part of any standard pre-employment screen unless the employer asks for them. Settings where you might see them:

  • Federal contracting, military, or DOT-regulated transportation roles — sometimes, depending on agency and contract
  • Substance-abuse treatment programs where kratom monitoring is part of the program
  • Pain management clinics doing comprehensive medication monitoring
  • Some healthcare systems in roles where opioid policies are stringent
  • Forensic and legal contexts where kratom use is being specifically investigated

For routine corporate or general workplace screens, kratom is almost never on the panel. If you're not sure whether your test will include kratom, you can ask the testing administrator directly — the test code on the requisition will tell you.

How long kratom stays detectable

Detection windows depend on dose, frequency of use, body composition, and the specific test format. The published estimate of mitragynine's elimination half-life in humans is roughly 23–24 hours, which translates to a practical detection window like this:

  • Occasional use (a few times a month): Detectable in urine via LC-MS/MS for roughly 3–5 days after the last dose
  • Moderate regular use (a few times a week): Detectable for 5–9 days
  • Daily heavy use: Detectable for 1–2 weeks
  • Hair testing: Theoretical detection window of 90+ days, though kratom hair tests are rare and not commercially standard
  • Blood testing: Mitragynine appears in blood within 30 minutes of use and remains detectable for roughly 24 hours
  • Saliva testing: Detectable for roughly 1–2 days, though this format is uncommon for kratom

The false-positive question

A common worry: will kratom cause a false positive for opiates on the standard screen? Generally no. Mitragynine and 7-OH are structurally distinct from morphine and codeine and do not reliably trigger the antibody assays used in opiate immunoassay screens.

That said, there are scattered case reports of cross-reactivity in certain rapid screening products. Standard practice in any properly run drug-testing program is to confirm positive screens with GC-MS or LC-MS/MS — the confirmatory test definitively identifies the compound present, and would distinguish mitragynine from a true opioid. If you take kratom and a screen unexpectedly comes back positive for opiates, request the confirmatory test in writing before any employment or legal action is taken on the result.

Disclosure — when and how

Whether to disclose kratom use ahead of a drug test is contextual. Some practical guidance:

  • For routine corporate screens that won't include kratom: there is nothing on the test to disclose for. Whether you mention kratom to your employer is a personal choice.
  • For regulated-industry pre-employment (federal, DOT, healthcare): if you're a regular kratom user, telling the medical review officer (MRO) up front gives them the context they need to interpret a specialty-panel result. Failing to disclose and then testing positive on a specialty kratom panel can look evasive even when the kratom use itself is legal.
  • For court-ordered or treatment-program testing: follow program rules. Many treatment programs explicitly prohibit kratom; check before assuming it's allowed.

The legal context matters too

Kratom is legal at the federal level in the United States and in most states. But testing positive for it on a specialty panel can still have employment consequences in jurisdictions or roles where the employer has a stated policy against kratom use. The presence of legality and the absence of a workplace policy are two different things.

For a state-by-state look at where kratom is legal, see our 2026 kratom legality guide. For the regulatory context that protects consumers in states that have moved on it, see our KCPA explainer.

The short answer

For the vast majority of workplace drug tests in the United States in 2026, kratom will not show up. Standard 5- and 10-panel screens don't test for it. Specialty kratom panels exist but have to be ordered specifically, and are uncommon outside regulated industries and treatment-program contexts. Half-life data suggests detection windows of 3–9 days for most users on a specialty panel.

If you have a specific test coming up and the result matters to your job, the right move is to ask the testing administrator what panel is being run — not to guess.